The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Blueprint Medicines Corp shares valued at $946,000 were purchased by LONNEL COATS on Nov 20 ’24. At $94.60 per share, LONNEL COATS acquired 10,000 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Albers Jeffrey W. sold 5,000 shares, netting a total of over 510,000 in proceeds. Following the sale of shares at $102.00 each, the insider now holds 157,557 shares.
Before that, Albers Jeffrey W. had added 5,000 shares to its account. In a trade valued at $510,000, the Director bought Blueprint Medicines Corp shares for $102.00 each.
As published in their initiating research note from JP Morgan on November 14, 2024, Blueprint Medicines Corp [BPMC] has been an Overweight and the price target has been revised to $126. Analysts at UBS started covering the stock with ‘”a Neutral”‘ outlook in a report released in late October. As of May 14, 2024, Stephens has initiated its “an Overweight” rating for BPMC. Earlier on May 06, 2024, Leerink Partners upgraded its rating. Their new recommendation was “a Market perform” for BPMC stock which previously was a “an Underperform”.
Analyzing BPMC Stock Performance
During the last five days, there has been a drop of approximately -2.14%. Over the course of the year, Blueprint Medicines Corp shares have jumped approximately 2.79%. Shares of the company reached a 52-week high of $121.90 on 07/16/24 and a 52-week low of $72.24 on 02/14/24. A 50-day SMA is recorded $90.00, while a 200-day SMA reached $95.89. Nevertheless, trading volume fell to 0.56 million shares from 0.63 million shares the previous day.
Support And Resistance Levels for Blueprint Medicines Corp (BPMC)
According to the 24-hour chart, there is a support level at 93.31, which, if violated, would cause prices to drop to 91.80. In the upper region, resistance lies at 95.67. The next price resistance is at 96.52. RSI (Relative Strength Index) is 54.43 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -2.47, which suggests the price will decrease in the coming days. Percent R is at 53.72%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
